$ITOS
Iteos Therapeutics Inc

2023 Q1 Form 10-K Financial Statement

#000095017023007971 Filed on March 15, 2023

View on sec.gov

Income Statement

Concept 2023 Q1 2022 Q4 2022
Revenue $12.60M $53.91M $267.6M
YoY Change -91.74% -77.59% -22.38%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $11.93M $11.10M $43.95M
YoY Change 12.36% 15.66% 8.5%
% of Gross Profit
Research & Development $25.60M $25.42M $97.36M
YoY Change 21.34% 46.22% 63.99%
% of Gross Profit
Depreciation & Amortization $222.0K $223.0K $803.0K
YoY Change 23.33% 47.68% 33.17%
% of Gross Profit
Operating Expenses $37.53M $36.52M $141.3M
YoY Change 18.33% 35.35% 41.48%
Operating Profit -$24.93M $126.3M
YoY Change -120.64% -48.42%
Interest Expense $7.851M $11.36M $11.36M
YoY Change
% of Operating Profit 8.99%
Other Income/Expense, Net $1.649M -$5.998M $7.788M
YoY Change -181.51% -156.99% 463.53%
Pretax Income -$14.35M $22.75M $148.7M
YoY Change -112.01% -89.85% -42.01%
Income Tax $1.199M $2.293M $52.08M
% Of Pretax Income 10.08% 35.02%
Net Earnings -$15.60M $20.45M $96.70M
YoY Change -122.42% -88.94% -54.92%
Net Earnings / Revenue -123.86% 37.94% 36.13%
Basic Earnings Per Share -$0.44 $2.72
Diluted Earnings Per Share -$0.44 $0.55 $2.56
COMMON SHARES
Basic Shares Outstanding 35.72M 35.58M 35.55M
Diluted Shares Outstanding 35.72M 37.77M

Balance Sheet

Concept 2023 Q1 2022 Q4 2022
SHORT-TERM ASSETS
Cash & Short-Term Investments $602.1M $613.2M $613.2M
YoY Change -26.92% -27.74% -27.74%
Cash & Equivalents $225.4M $284.8M $284.8M
Short-Term Investments $376.8M $328.4M $328.4M
Other Short-Term Assets $12.60M $12.70M $12.70M
YoY Change 4.47% -9.83% -9.83%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $615.4M $628.3M $628.3M
YoY Change -26.8% -28.17% -28.17%
LONG-TERM ASSETS
Property, Plant & Equipment $2.119M $2.121M $6.773M
YoY Change -4.38% 2.36% -8.49%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments $104.5M $118.2M $118.2M
YoY Change
Other Assets $329.0K $332.0K $567.0K
YoY Change 4.11% 12.16% -4.55%
Total Long-Term Assets $112.9M $126.7M $126.7M
YoY Change 1069.08% 1167.06% 1167.06%
TOTAL ASSETS
Total Short-Term Assets $615.4M $628.3M $628.3M
Total Long-Term Assets $112.9M $126.7M $126.7M
Total Assets $728.3M $755.0M $755.0M
YoY Change -14.34% -14.66% -14.66%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $5.694M $7.662M $7.662M
YoY Change -46.3% 48.92% 48.92%
Accrued Expenses $17.73M $19.73M $20.56M
YoY Change 26.15% 14.98% 14.7%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $26.36M $42.00M $42.00M
YoY Change -84.87% -86.19% -86.19%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities $49.73M $0.00 $49.66M
YoY Change 165653.33% -100.0% 78.84%
Total Long-Term Liabilities $49.73M $0.00 $49.66M
YoY Change 165653.33% -100.0% 78.84%
TOTAL LIABILITIES
Total Short-Term Liabilities $26.36M $42.00M $42.00M
Total Long-Term Liabilities $49.73M $0.00 $49.66M
Total Liabilities $76.08M $91.66M $91.66M
YoY Change -66.03% -72.38% -72.38%
SHAREHOLDERS EQUITY
Retained Earnings $221.7M $237.3M
YoY Change 5.47% 68.75%
Common Stock $36.00K $36.00K
YoY Change 0.0% 2.86%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $652.3M $663.3M $663.3M
YoY Change
Total Liabilities & Shareholders Equity $728.3M $755.0M $755.0M
YoY Change -14.34% -14.66% -14.66%

Cashflow Statement

Concept 2023 Q1 2022 Q4 2022
OPERATING ACTIVITIES
Net Income -$15.60M $20.45M $96.70M
YoY Change -122.42% -88.94% -54.92%
Depreciation, Depletion And Amortization $222.0K $223.0K $803.0K
YoY Change 23.33% 47.68% 33.17%
Cash From Operating Activities -$26.56M -$27.17M -$111.2M
YoY Change 10.64% -53.8% -121.67%
INVESTING ACTIVITIES
Capital Expenditures $119.0K $116.0K $938.0K
YoY Change -47.58% -172.05% -20.58%
Acquisitions
YoY Change
Other Investing Activities -$31.58M -$445.0M -$445.0M
YoY Change
Cash From Investing Activities -$31.69M -$445.1M -$446.1M
YoY Change 9712.38% 276372.05% 35814.81%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $925.0K
YoY Change -68.57%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 578.0K 1.374M 1.984M
YoY Change 73.57% -41.68% -45.78%
NET CHANGE
Cash From Operating Activities -26.56M -27.17M -111.2M
Cash From Investing Activities -31.69M -445.1M -446.1M
Cash From Financing Activities 578.0K 1.374M 1.984M
Net Change In Cash -59.44M -470.9M -563.8M
YoY Change 142.08% 731.7% -210.03%
FREE CASH FLOW
Cash From Operating Activities -$26.56M -$27.17M -$111.2M
Capital Expenditures $119.0K $116.0K $938.0K
Free Cash Flow -$26.67M -$27.29M -$112.1M
YoY Change 10.09% -53.48% -121.9%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2022 dei Amendment Flag
AmendmentFlag
false
CY2021Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2022Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2022 dei Entity Central Index Key
EntityCentralIndexKey
0001808865
CY2022 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2022 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
FY
CY2022 dei Document Type
DocumentType
10-K
CY2022 dei Document Annual Report
DocumentAnnualReport
true
CY2022 dei Document Period End Date
DocumentPeriodEndDate
2022-12-31
CY2022 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2022
CY2022 dei Document Transition Report
DocumentTransitionReport
false
CY2022 dei Entity File Number
EntityFileNumber
001-39401
CY2022 dei Entity Registrant Name
EntityRegistrantName
iTeos Therapeutics, Inc.
CY2022 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
CY2022 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
84-3365066
CY2022 dei Entity Address Address Line1
EntityAddressAddressLine1
321 Arsenal St
CY2022 dei Entity Address City Or Town
EntityAddressCityOrTown
Watertown
CY2022 dei Entity Address State Or Province
EntityAddressStateOrProvince
MA
CY2022 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
02472
CY2022 dei City Area Code
CityAreaCode
339
CY2022 dei Local Phone Number
LocalPhoneNumber
217 0161
CY2022 dei Security12b Title
Security12bTitle
Common stock, $0.001 par value per share
CY2022 dei Trading Symbol
TradingSymbol
ITOS
CY2022 dei Security Exchange Name
SecurityExchangeName
NASDAQ
CY2022 dei Entity Well Known Seasoned Issuer
EntityWellKnownSeasonedIssuer
No
CY2022 dei Entity Voluntary Filers
EntityVoluntaryFilers
No
CY2022 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2022 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2022 dei Entity Filer Category
EntityFilerCategory
Accelerated Filer
CY2022 dei Entity Small Business
EntitySmallBusiness
false
CY2022 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
CY2022 dei Entity Ex Transition Period
EntityExTransitionPeriod
false
CY2022 dei Icfr Auditor Attestation Flag
IcfrAuditorAttestationFlag
false
CY2022 dei Entity Shell Company
EntityShellCompany
false
CY2023Q1 dei Entity Public Float
EntityPublicFloat
609700000
CY2023Q1 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
35720401
CY2022 dei Auditor Firm
AuditorFirmId
1133
CY2022 dei Auditor Name
AuditorName
Deloitte Bedrijfsrevisoren/Réviseurs d’Entreprises BV/SRL
CY2022 dei Auditor Location
AuditorLocation
Zaventem, Belgium
CY2022Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
284803000
CY2021Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
848537000
CY2022Q4 us-gaap Debt Securities Available For Sale Amortized Cost Current
DebtSecuritiesAvailableForSaleAmortizedCostCurrent
328405000
CY2022Q4 us-gaap Short Term Investments
ShortTermInvestments
328359000
CY2021Q4 us-gaap Short Term Investments
ShortTermInvestments
0
CY2022Q4 us-gaap Grants Receivable Current
GrantsReceivableCurrent
1001000
CY2021Q4 us-gaap Grants Receivable Current
GrantsReceivableCurrent
4022000
CY2022Q4 itos Research And Development Tax Credit Receivable Current
ResearchAndDevelopmentTaxCreditReceivableCurrent
0
CY2021Q4 itos Research And Development Tax Credit Receivable Current
ResearchAndDevelopmentTaxCreditReceivableCurrent
524000
CY2022Q4 us-gaap Income Tax Receivable
IncomeTaxReceivable
1434000
CY2021Q4 us-gaap Income Tax Receivable
IncomeTaxReceivable
7544000
CY2022Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
12701000
CY2021Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
14086000
CY2022Q4 us-gaap Assets Current
AssetsCurrent
628298000
CY2021Q4 us-gaap Assets Current
AssetsCurrent
874713000
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
2121000
CY2021Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
2072000
CY2022Q4 us-gaap Debt Securities Available For Sale Amortized Cost Noncurrent
DebtSecuritiesAvailableForSaleAmortizedCostNoncurrent
118330000
CY2022Q4 us-gaap Long Term Investments
LongTermInvestments
118225000
CY2021Q4 us-gaap Long Term Investments
LongTermInvestments
0
CY2022Q4 itos Research And Development Tax Credit Receivable Non Current
ResearchAndDevelopmentTaxCreditReceivableNonCurrent
1128000
CY2021Q4 itos Research And Development Tax Credit Receivable Non Current
ResearchAndDevelopmentTaxCreditReceivableNonCurrent
2004000
CY2022Q4 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
235000
CY2021Q4 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
298000
CY2022Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
4652000
CY2021Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
5329000
CY2022Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
332000
CY2021Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
296000
CY2022Q4 us-gaap Assets
Assets
754991000
CY2021Q4 us-gaap Assets
Assets
884712000
CY2022Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
7662000
CY2021Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
5145000
CY2022Q4 us-gaap Accounts Payable And Other Accrued Liabilities Current
AccountsPayableAndOtherAccruedLiabilitiesCurrent
19727000
CY2021Q4 us-gaap Accounts Payable And Other Accrued Liabilities Current
AccountsPayableAndOtherAccruedLiabilitiesCurrent
17157000
CY2022Q4 us-gaap Deferred Income Current
DeferredIncomeCurrent
1180000
CY2021Q4 us-gaap Deferred Income Current
DeferredIncomeCurrent
827000
CY2022Q4 us-gaap Deferred Revenue
DeferredRevenue
12595000
CY2021Q4 us-gaap Deferred Revenue
DeferredRevenue
280225000
CY2022Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
836000
CY2021Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
770000
CY2022Q4 us-gaap Liabilities Current
LiabilitiesCurrent
42000000
CY2021Q4 us-gaap Liabilities Current
LiabilitiesCurrent
304124000
CY2022Q4 itos Grants Repayable
GrantsRepayable
6622000
CY2021Q4 itos Grants Repayable
GrantsRepayable
6164000
CY2022Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
3837000
CY2021Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
4571000
CY2022Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
39200000
CY2021Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
17000000
CY2022Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
0
CY2021Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
33000
CY2022Q4 us-gaap Liabilities
Liabilities
91659000
CY2021Q4 us-gaap Liabilities
Liabilities
331892000
CY2022Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2021Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2022Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
150000000
CY2021Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
150000000
CY2022Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
35611219
CY2022Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
35611219
CY2021Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
35466001
CY2021Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
35466001
CY2022Q4 us-gaap Common Stock Value
CommonStockValue
36000
CY2021Q4 us-gaap Common Stock Value
CommonStockValue
35000
CY2022Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
435665000
CY2021Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
413180000
CY2022Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-9644000
CY2021Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-1018000
CY2022Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
237275000
CY2021Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
140623000
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
663332000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
552820000
CY2022Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
754991000
CY2021Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
884712000
CY2022 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
267630000
CY2021 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
344775000
CY2022 us-gaap Revenues
Revenues
267630000
CY2021 us-gaap Revenues
Revenues
344775000
CY2022 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
97359000
CY2021 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
59369000
CY2022 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
43947000
CY2021 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
40505000
CY2022 us-gaap Operating Expenses
OperatingExpenses
141306000
CY2021 us-gaap Operating Expenses
OperatingExpenses
99874000
CY2022 us-gaap Operating Income Loss
OperatingIncomeLoss
126324000
CY2021 us-gaap Operating Income Loss
OperatingIncomeLoss
244901000
CY2022 itos Grant Income
GrantIncome
2091000
CY2021 itos Grant Income
GrantIncome
10181000
CY2022 itos Research And Development Tax Credits
ResearchAndDevelopmentTaxCredits
1172000
CY2021 itos Research And Development Tax Credits
ResearchAndDevelopmentTaxCredits
0
CY2022 us-gaap Interest Income Other
InterestIncomeOther
11361000
CY2021 us-gaap Interest Income Other
InterestIncomeOther
78000
CY2022 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
7788000
CY2021 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
1304000
CY2022 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
148736000
CY2021 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
256464000
CY2022 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
52084000
CY2021 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
41943000
CY2022 us-gaap Net Income Loss
NetIncomeLoss
96652000
CY2021 us-gaap Net Income Loss
NetIncomeLoss
214521000
CY2022 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
96652000
CY2021 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
214521000
CY2022 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
2.72
CY2021 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
6.10
CY2022 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
2.56
CY2021 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
5.68
CY2022 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
35552025
CY2021 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
35181383
CY2022 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
37766507
CY2021 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
37774790
CY2022 us-gaap Net Income Loss
NetIncomeLoss
96652000
CY2021 us-gaap Net Income Loss
NetIncomeLoss
214521000
CY2022 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-8478000
CY2021 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-1635000
CY2022 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
-148000
CY2022 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
88026000
CY2021 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
212886000
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
323197000
CY2021 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
13794000
CY2021 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
2943000
CY2021 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax
-1635000
CY2021 us-gaap Net Income Loss
NetIncomeLoss
214521000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
552820000
CY2022 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
21561000
CY2022 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
925000
CY2022 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax
-8478000
CY2022 us-gaap Debt Securities Available For Sale Unrealized Gain Loss
DebtSecuritiesAvailableForSaleUnrealizedGainLoss
-148000
CY2022 us-gaap Net Income Loss
NetIncomeLoss
96652000
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
663332000
CY2022 us-gaap Profit Loss
ProfitLoss
96652000
CY2021 us-gaap Profit Loss
ProfitLoss
214521000
CY2022 us-gaap Depreciation And Amortization
DepreciationAndAmortization
803000
CY2021 us-gaap Depreciation And Amortization
DepreciationAndAmortization
603000
CY2022 us-gaap Share Based Compensation
ShareBasedCompensation
21561000
CY2021 us-gaap Share Based Compensation
ShareBasedCompensation
13794000
CY2022 itos Amortization Accretion Of Available For Sale Debt Securities
AmortizationAccretionOfAvailableForSaleDebtSecurities
-1728000
CY2021 itos Amortization Accretion Of Available For Sale Debt Securities
AmortizationAccretionOfAvailableForSaleDebtSecurities
0
CY2022 itos Change In Operating Lease Right Of Use Assets
ChangeInOperatingLeaseRightOfUseAssets
10000
CY2021 itos Change In Operating Lease Right Of Use Assets
ChangeInOperatingLeaseRightOfUseAssets
12000
CY2022 itos Increase Decrease In Grants Receivable
IncreaseDecreaseInGrantsReceivable
2751000
CY2021 itos Increase Decrease In Grants Receivable
IncreaseDecreaseInGrantsReceivable
-4071000
CY2022 itos Increase Decrease In Research And Development Tax Credit Receivable
IncreaseDecreaseInResearchAndDevelopmentTaxCreditReceivable
-1237000
CY2021 itos Increase Decrease In Research And Development Tax Credit Receivable
IncreaseDecreaseInResearchAndDevelopmentTaxCreditReceivable
-727000
CY2022 itos Refundable Income Taxes
RefundableIncomeTaxes
6107000
CY2021 itos Refundable Income Taxes
RefundableIncomeTaxes
-7544000
CY2022 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-590000
CY2021 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
11789000
CY2022 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
2761000
CY2021 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
2280000
CY2022 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
3096000
CY2021 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
9959000
CY2022 us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
397000
CY2021 us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
-3480000
CY2022 us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
-267630000
CY2021 us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
281128000
CY2022 itos Increase Decrease In Unrecognized Tax Benefits
IncreaseDecreaseInUnrecognizedTaxBenefits
-22200000
CY2021 itos Increase Decrease In Unrecognized Tax Benefits
IncreaseDecreaseInUnrecognizedTaxBenefits
-17000000
CY2022 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-111193000
CY2021 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
513140000
CY2022 us-gaap Payments To Acquire Investments
PaymentsToAcquireInvestments
445004000
CY2022 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
938000
CY2021 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
1181000
CY2022 us-gaap Payments To Acquire Other Productive Assets
PaymentsToAcquireOtherProductiveAssets
120000
CY2021 us-gaap Payments To Acquire Other Productive Assets
PaymentsToAcquireOtherProductiveAssets
61000
CY2022 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-446062000
CY2021 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-1242000
CY2022 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
925000
CY2021 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
2943000
CY2022 us-gaap Proceeds From Repayments Of Related Party Debt
ProceedsFromRepaymentsOfRelatedPartyDebt
1059000
CY2021 us-gaap Proceeds From Repayments Of Related Party Debt
ProceedsFromRepaymentsOfRelatedPartyDebt
716000
CY2022 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
1984000
CY2021 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
3659000
CY2022 us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
-8526000
CY2021 us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
-3176000
CY2022 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-563797000
CY2021 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
512381000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
848835000
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
336454000
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
285038000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
848835000
CY2022 itos Capital Expenditure Included In Accounts Payable
CapitalExpenditureIncludedInAccountsPayable
94000
CY2021 itos Capital Expenditure Included In Accounts Payable
CapitalExpenditureIncludedInAccountsPayable
175000
CY2022 us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
350000
CY2021 us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
5877000
CY2022 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Before Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeTax
148000
CY2022 us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
22816000
CY2021 us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
32019000
CY2021 us-gaap Net Income Loss
NetIncomeLoss
214500000
CY2022 us-gaap Net Income Loss
NetIncomeLoss
96700000
CY2022Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
237300000
CY2022 us-gaap Use Of Estimates
UseOfEstimates
<p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;">Use of estimates</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">The preparation of the Company’s consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenue, and expenses, as well as the related disclosures of contingent assets and liabilities. The Company bases its estimates and assumptions on historical experiences, when available, and on various factors that it believes to be reasonable under the circumstances. The Company evaluates its estimates and assumptions on an ongoing basis. Actual results could differ materially from these estimates.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">The full extent to which the COVID-19 pandemic will directly or indirectly impact the Company’s business, results of operations and financial condition, including expenses, research and development costs and employee-related amounts, will depend on future developments that are highly uncertain, including as a result of new information that may emerge concerning COVID-19 and the actions taken to contain or treat COVID-19, as well as the economic impact on local, regional, national and international markets. The Company has considered the impact of COVID-19 on estimates within its financial statements and there may be changes to those estimates in future periods. As of the date of issuance of these consolidated financial statements, the Company has not experienced material business disruptions or incurred impairment losses in the carrying value of its assets as a result of the pandemic and is not aware of any specific related event or circumstance that would require it to update its estimates.</span></p>
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
40745000
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
6401987
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
18.50
CY2022 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
P7Y1M6D
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
40745000
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
3278177
CY2022Q4 itos Fair Value Assets Level1 To Level2 Transfers Amount1
FairValueAssetsLevel1ToLevel2TransfersAmount1
0
CY2021Q4 itos Fair Value Assets Level1 To Level2 Transfers Amount1
FairValueAssetsLevel1ToLevel2TransfersAmount1
0
CY2022 us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;">Concentration of credit risk</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">As of December 31, 2022 and 2021, the Company’s cash and cash equivalents consisted primarily of cash balances held in U.S. dollars in money market funds and money market accounts and euro in accounts with European banks in excess of publicly insured limits. The Company does not believe it is subject to unusual credit risk associated with commercial banking relationships.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">As of December 31, 2022, the Company's fixed income securities consisted of investment grade U.S. treasury, U.S. government agency, and corporate securities. There are no securities in the Company's portfolio with a credit rating below "A-". Approximately </span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">99</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">% of the Company's fixed income holdings as of December 31, 2022 consisted of U.S. treasury and U.S. government agency securities. The Company does not believe it is subject to unusual credit risk associated with its investment portfolio.</span></p>
CY2022 itos Research And Development Tax Credits Percentage
ResearchAndDevelopmentTaxCreditsPercentage
0.135
CY2021 itos Research And Development Tax Credits Percentage
ResearchAndDevelopmentTaxCreditsPercentage
0.135
CY2022 us-gaap Property Plant And Equipment Estimated Useful Lives
PropertyPlantAndEquipmentEstimatedUsefulLives
Shorter of useful life or term of lease
CY2022 us-gaap Impairment Of Long Lived Assets Held For Use
ImpairmentOfLongLivedAssetsHeldForUse
0
CY2021 us-gaap Impairment Of Long Lived Assets Held For Use
ImpairmentOfLongLivedAssetsHeldForUse
0
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
12.79
CY2022 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P6Y3M18D
CY2022Q4 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
29670000
CY2021Q1 itos Right To Use Assets And Lease Liabilities
RightToUseAssetsAndLeaseLiabilities
900000
CY2022 us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1
CY2021Q4 us-gaap Cash And Cash Equivalents Fair Value Disclosure
CashAndCashEquivalentsFairValueDisclosure
797448000
CY2021Q4 us-gaap Cash And Cash Equivalents Fair Value Disclosure
CashAndCashEquivalentsFairValueDisclosure
797448000
CY2022 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers Net
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet
0
CY2021 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers Net
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet
0
CY2022Q4 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
446735000
CY2022Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
106000
CY2022Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
257000
CY2022Q4 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
446584000
CY2022Q4 itos Available For Sale Debt Securities Unrealized Loss Difference
AvailableForSaleDebtSecuritiesUnrealizedLossDifference
3000
CY2022Q4 us-gaap Available For Sale Securities Debt Maturities Within One Year Amortized Cost
AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost
328405000
CY2022Q4 us-gaap Available For Sale Securities Debt Maturities Within One Year Fair Value
AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue
328359000
CY2022Q4 us-gaap Available For Sale Securities Debt Maturities After One Through Five Years Amortized Cost
AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost
118330000
CY2022Q4 us-gaap Available For Sale Securities Debt Maturities After One Through Five Years Fair Value
AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue
118225000
CY2022Q4 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
446735000
CY2022Q4 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
446584000
CY2022 us-gaap Proceeds From Sale Of Available For Sale Securities Debt
ProceedsFromSaleOfAvailableForSaleSecuritiesDebt
1800000
CY2022Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
5578000
CY2021Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
5043000
CY2022Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
3457000
CY2021Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
2971000
CY2020Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
2121000
CY2021Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
2072000
CY2022 us-gaap Depreciation And Amortization
DepreciationAndAmortization
800000
CY2021 us-gaap Depreciation And Amortization
DepreciationAndAmortization
600000
CY2022Q4 itos Accrued Clinical Trial Costs Current
AccruedClinicalTrialCostsCurrent
13496000
CY2021Q4 itos Accrued Clinical Trial Costs Current
AccruedClinicalTrialCostsCurrent
12991000
CY2022Q4 itos Accrued Personnel Costs Current
AccruedPersonnelCostsCurrent
5635000
CY2021Q4 itos Accrued Personnel Costs Current
AccruedPersonnelCostsCurrent
3884000
CY2022Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
64000
CY2021Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
25000
CY2022Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
532000
CY2021Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
257000
CY2022Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
19727000
CY2021Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
17157000
CY2022 itos Upfront Payment Received
UpfrontPaymentReceived
625000000.0
CY2021Q4 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
280225000
CY2022 itos Contract With Customer Liability Deductions
ContractWithCustomerLiabilityDeductions
-267630000
CY2022Q4 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
12595000
CY2022 us-gaap Research And Development Arrangement With Federal Government Costs Incurred Net
ResearchAndDevelopmentArrangementWithFederalGovernmentCostsIncurredNet
7400000
CY2022 itos Proceeds Received From Grants
ProceedsReceivedFromGrants
6261000
CY2021 itos Proceeds Received From Grants
ProceedsReceivedFromGrants
3167000
CY2022 itos Grant Income
GrantIncome
2091000
CY2021 itos Grant Income
GrantIncome
10181000
CY2022Q4 us-gaap Grants Receivable Current
GrantsReceivableCurrent
1001000
CY2021Q4 us-gaap Grants Receivable Current
GrantsReceivableCurrent
4022000
CY2022Q4 us-gaap Deferred Income Noncurrent
DeferredIncomeNoncurrent
6977000
CY2021Q4 us-gaap Deferred Income Noncurrent
DeferredIncomeNoncurrent
6164000
CY2022 us-gaap Common Stock Voting Rights
CommonStockVotingRights
Each share of common stock entitles the holders to one vote on all matters submitted to a vote of the Company’s stockholders.
CY2022 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Award Vesting Rights Percentage
SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage
0.25
CY2022 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Award Vesting Period1
ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
P36M
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
5207084
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
14.35
CY2021 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P7Y8M12D
CY2022 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
1361467
CY2022 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
32.80
CY2022 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
39086
CY2022 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
8.00
CY2022 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
127478
CY2022 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
5.21
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
6401987
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
18.50
CY2022 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P7Y1M6D
CY2022 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
21561000
CY2021 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
13794000
CY2022 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
23.94
CY2021 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
27.46
CY2022 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
3200000
CY2021 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
11000000.0
CY2022 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
20400000
CY2021 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
10700000
CY2022 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
0.0137
CY2022 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
0.0423
CY2021 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
0.0042
CY2021 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
0.0127
CY2022 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
0.86
CY2022 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
0.94
CY2021 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
0.92
CY2021 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
1
CY2022 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
CY2021 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
CY2022 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0163
CY2021 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0
CY2022 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P0Y6M
CY2022 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.81
CY2021 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0
CY2022 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
CY2021 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
CY2022 itos Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Common Stock
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsCommonStock
17.30
CY2021 itos Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Common Stock
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsCommonStock
0
CY2022 us-gaap Income Loss From Continuing Operations Before Income Taxes Domestic
IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
-72940000
CY2021 us-gaap Income Loss From Continuing Operations Before Income Taxes Domestic
IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
-47242000
CY2022 us-gaap Income Loss From Continuing Operations Before Income Taxes Foreign
IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
221676000
CY2021 us-gaap Income Loss From Continuing Operations Before Income Taxes Foreign
IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
303706000
CY2022 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
148736000
CY2021 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
256464000
CY2022 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.350
CY2021 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.164
CY2022 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.21
CY2021 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.21
CY2022 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.210
CY2021 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.210
CY2022 itos Effective Income Tax Rate Reconciliation State Income Taxes Percent
EffectiveIncomeTaxRateReconciliationStateIncomeTaxesPercent
-0.022
CY2021 itos Effective Income Tax Rate Reconciliation State Income Taxes Percent
EffectiveIncomeTaxRateReconciliationStateIncomeTaxesPercent
-0.005
CY2022 us-gaap Effective Income Tax Rate Reconciliation Foreign Income Tax Rate Differential
EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential
0.052
CY2021 us-gaap Effective Income Tax Rate Reconciliation Foreign Income Tax Rate Differential
EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential
0.047
CY2022 itos Effective Income Tax Rate Reconciliation Relating To Non Taxable Income And Non Deductible Expense
EffectiveIncomeTaxRateReconciliationRelatingToNonTaxableIncomeAndNonDeductibleExpense
0.001
CY2021 itos Effective Income Tax Rate Reconciliation Relating To Non Taxable Income And Non Deductible Expense
EffectiveIncomeTaxRateReconciliationRelatingToNonTaxableIncomeAndNonDeductibleExpense
0.001
CY2022 us-gaap Effective Income Tax Rate Reconciliation Tax Exempt Income
EffectiveIncomeTaxRateReconciliationTaxExemptIncome
-0.334
CY2021 us-gaap Effective Income Tax Rate Reconciliation Tax Exempt Income
EffectiveIncomeTaxRateReconciliationTaxExemptIncome
-0.282
CY2022 itos Effective Income Tax Rate Reconciliation Net Gilti Inclusion Income
EffectiveIncomeTaxRateReconciliationNetGiltiInclusionIncome
0.189
CY2021 itos Effective Income Tax Rate Reconciliation Net Gilti Inclusion Income
EffectiveIncomeTaxRateReconciliationNetGiltiInclusionIncome
0.152
CY2022 itos Effective Income Tax Rate Unrecognized Tax Benefits
EffectiveIncomeTaxRateUnrecognizedTaxBenefits
0.149
CY2021 itos Effective Income Tax Rate Unrecognized Tax Benefits
EffectiveIncomeTaxRateUnrecognizedTaxBenefits
0.066
CY2022 us-gaap Effective Income Tax Rate Reconciliation Other Reconciling Items Percent
EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent
-0.030
CY2021 us-gaap Effective Income Tax Rate Reconciliation Other Reconciling Items Percent
EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent
-0.011
CY2022 itos Effective Income Tax Rate Reconciliation Change In Valuation Allowance Percent
EffectiveIncomeTaxRateReconciliationChangeInValuationAllowancePercent
0.135
CY2021 itos Effective Income Tax Rate Reconciliation Change In Valuation Allowance Percent
EffectiveIncomeTaxRateReconciliationChangeInValuationAllowancePercent
-0.014
CY2022 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.350
CY2021 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.164
CY2022 us-gaap Current Federal State And Local Tax Expense Benefit
CurrentFederalStateAndLocalTaxExpenseBenefit
50750000
CY2021 us-gaap Current Federal State And Local Tax Expense Benefit
CurrentFederalStateAndLocalTaxExpenseBenefit
41535000
CY2022 us-gaap Current Foreign Tax Expense Benefit
CurrentForeignTaxExpenseBenefit
1334000
CY2021 us-gaap Current Foreign Tax Expense Benefit
CurrentForeignTaxExpenseBenefit
408000
CY2022 us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
0
CY2021 us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
0
CY2022 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
52084000
CY2021 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
41943000
CY2022Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
13359000
CY2021Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
17097000
CY2022Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards Foreign
DeferredTaxAssetsTaxCreditCarryforwardsForeign
12355000
CY2021Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards Foreign
DeferredTaxAssetsTaxCreditCarryforwardsForeign
7884000
CY2022Q4 itos Section174 Capitalized Research And Development Expenses
Section174CapitalizedResearchAndDevelopmentExpenses
14856000
CY2021Q4 itos Section174 Capitalized Research And Development Expenses
Section174CapitalizedResearchAndDevelopmentExpenses
0
CY2022Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
3860000
CY2021Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
1784000
CY2022Q4 itos Deferred Tax Assets Operating Lease Liabilities
DeferredTaxAssetsOperatingLeaseLiabilities
1201000
CY2021Q4 itos Deferred Tax Assets Operating Lease Liabilities
DeferredTaxAssetsOperatingLeaseLiabilities
1374000
CY2022Q4 itos Deferred Tax Aseets Accrued Vacation And Bonus
DeferredTaxAseetsAccruedVacationAndBonus
552000
CY2021Q4 itos Deferred Tax Aseets Accrued Vacation And Bonus
DeferredTaxAseetsAccruedVacationAndBonus
390000
CY2022Q4 us-gaap Deferred Tax Assets Other
DeferredTaxAssetsOther
932000
CY2021Q4 us-gaap Deferred Tax Assets Other
DeferredTaxAssetsOther
17000
CY2022Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
47115000
CY2021Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
28546000
CY2022Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
45421000
CY2021Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
26647000
CY2022Q4 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
1694000
CY2021Q4 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
1899000
CY2022Q4 us-gaap Deferred Tax Liabilities Other Finite Lived Assets
DeferredTaxLiabilitiesOtherFiniteLivedAssets
1196000
CY2021Q4 us-gaap Deferred Tax Liabilities Other Finite Lived Assets
DeferredTaxLiabilitiesOtherFiniteLivedAssets
1371000
CY2022Q4 us-gaap Deferred Tax Liabilities Prepaid Expenses
DeferredTaxLiabilitiesPrepaidExpenses
394000
CY2021Q4 us-gaap Deferred Tax Liabilities Prepaid Expenses
DeferredTaxLiabilitiesPrepaidExpenses
497000
CY2022Q4 itos Deferred Tax Liabilities Depreciation And Amortization
DeferredTaxLiabilitiesDepreciationAndAmortization
104000
CY2021Q4 itos Deferred Tax Liabilities Depreciation And Amortization
DeferredTaxLiabilitiesDepreciationAndAmortization
31000
CY2022Q4 us-gaap Deferred Income Tax Liabilities
DeferredIncomeTaxLiabilities
1694000
CY2021Q4 us-gaap Deferred Income Tax Liabilities
DeferredIncomeTaxLiabilities
1899000
CY2022Q4 us-gaap Deferred Tax Liabilities
DeferredTaxLiabilities
0
CY2021Q4 us-gaap Deferred Tax Liabilities
DeferredTaxLiabilities
0
CY2022 us-gaap Valuation Allowance Deferred Tax Asset Change In Amount
ValuationAllowanceDeferredTaxAssetChangeInAmount
18800000
CY2020 itos Net Operating Loss Carry Forwards Deductible At Maximum Rate Of Corporations Taxable Income
NetOperatingLossCarryForwardsDeductibleAtMaximumRateOfCorporationsTaxableIncome
0.80
CY2017 itos Net Operating Loss Carry Forwards Deductible At Maximum Rate Of Corporations Taxable Income
NetOperatingLossCarryForwardsDeductibleAtMaximumRateOfCorporationsTaxableIncome
1
CY2022Q4 itos Net Operating Loss Available To Offset Rate For Taxable Income Limitation Under Tcja
NetOperatingLossAvailableToOffsetRateForTaxableIncomeLimitationUnderTCJA
0.80
CY2022Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards Domestic
DeferredTaxAssetsOperatingLossCarryforwardsDomestic
38400000
CY2022 itos Date Expiring De Minimis Federal Future Tax Liabilities
DateExpiringDeMinimisFederalFutureTaxLiabilities
2042
CY2022 itos Date Expiring State Tax Credit Available To Reduce Future Tax Liabilities
DateExpiringStateTaxCreditAvailableToReduceFutureTaxLiabilities
2037
CY2022Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
39200000
CY2021Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
17000000.0
CY2022Q4 us-gaap Unrecognized Tax Benefits Interest On Income Taxes Accrued
UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccrued
2200000
CY2021Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
17000000
CY2022 us-gaap Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions
UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
22200000
CY2022Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
39200000
CY2022Q4 us-gaap Land Subject To Ground Leases
LandSubjectToGroundLeases
1577
CY2022 us-gaap Other Commitments Description
OtherCommitmentsDescription
In January 2021, the Company entered into an amendment to extend the lease, effective February 2021 with a termination date of January 2030, and increase the office and laboratory space
CY2022 us-gaap Lease And Rental Expense
LeaseAndRentalExpense
900000
CY2021 us-gaap Lease And Rental Expense
LeaseAndRentalExpense
700000
CY2022Q4 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P5Y
CY2022Q4 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.0479
CY2022 us-gaap Income Loss From Continuing Operations
IncomeLossFromContinuingOperations
96652000
CY2021 us-gaap Income Loss From Continuing Operations
IncomeLossFromContinuingOperations
214521000
CY2022 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
35552025
CY2022 us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
350000
CY2022 us-gaap Operating Lease Payments
OperatingLeasePayments
860000
CY2022Q4 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
1059000
CY2022Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
1041000
CY2022Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
1010000
CY2022Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
980000
CY2022Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Five
LesseeOperatingLeaseLiabilityPaymentsDueYearFive
489000
CY2022Q4 us-gaap Lessee Operating Lease Liability Payments Due After Year Five
LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive
770000
CY2022Q4 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
5349000
CY2022Q4 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
676000
CY2022Q4 us-gaap Operating Lease Liability
OperatingLeaseLiability
4673000
CY2022Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
836000
CY2022Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
3837000
CY2022 us-gaap Defined Contribution Plan Employer Matching Contribution Percent
DefinedContributionPlanEmployerMatchingContributionPercent
0.05
CY2022 us-gaap Defined Benefit Plan Contributions By Employer
DefinedBenefitPlanContributionsByEmployer
398000
CY2021 us-gaap Defined Benefit Plan Contributions By Employer
DefinedBenefitPlanContributionsByEmployer
254000
CY2021 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
35181383
CY2022 us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
2214482
CY2021 us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
2593407
CY2022 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
37766507
CY2021 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
37774790
CY2022 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
2.72
CY2021 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
6.10
CY2022 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
2.56
CY2021 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
5.68

Files In Submission

Name View Source Status
0000950170-23-007971-index-headers.html Edgar Link pending
0000950170-23-007971-index.html Edgar Link pending
0000950170-23-007971.txt Edgar Link pending
0000950170-23-007971-xbrl.zip Edgar Link pending
Financial_Report.xlsx Edgar Link pending
img1255042_0.jpg Edgar Link pending
img163266043_0.jpg Edgar Link pending
img163266043_1.jpg Edgar Link pending
img163266043_2.jpg Edgar Link pending
itos-20221231.htm Edgar Link pending
itos-20221231.xsd Edgar Link pending
itos-ex10_14.htm Edgar Link pending
itos-ex10_15.htm Edgar Link pending
itos-ex10_18.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
itos-20221231_cal.xml Edgar Link unprocessable
itos-20221231_lab.xml Edgar Link unprocessable
itos-20221231_pre.xml Edgar Link unprocessable
itos-20221231_def.xml Edgar Link unprocessable
itos-20221231_htm.xml Edgar Link completed
itos-ex10_19.htm Edgar Link pending
itos-ex10_22.htm Edgar Link pending
itos-ex21_1.htm Edgar Link pending
itos-ex23_1.htm Edgar Link pending
itos-ex31_1.htm Edgar Link pending
itos-ex31_2.htm Edgar Link pending
itos-ex32_1.htm Edgar Link pending
itos-ex32_2.htm Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R61.htm Edgar Link pending
R62.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending